Treatment Options for CML Patients With the T315I KD MutationAkard, Luke P.Clinical Advances in Hematology & Oncology
Mauro, MD, director of the chronic myeloid leukemia (CML) program in the leukemia service at Memorial Sloan Kettering Cancer Center, discusses decision-making for patients with chronic myeloid leukemia (CML). CML is a complex disease and according to Mauro, decision-making often...
Initial treatment of CML patients with hydroxyurea is usually a daily dose of 1-4 grams, depending on the white blood count, presence of symptoms, and urgency to lower the white blood count. Leukapheresis is reserved for patients presenting with signs or symptoms of leukostasis. As the white ...
With such effective treatment options available, it is not surprising that overall survival in CML is tightly correlated to regimen adherence. This was displayed by Kim et al. in their retrospective study that revealed that five-year overall survival varied between 70.2%, 85.2%, and 97.2% for ...
AML induction therapy to be used when myeloid BP-CML and ALL induction therapy is recommended in lymphoid BP-CML. CNS prophylaxis is recommended for lymphoid type, as CNS involvement was reported. [32] The risk of relapse is high. Treatment options include donor lymphocyte infusion (DLI); ...
Current Front-Line Treatment Options for CLL in 2023 EP: 2.Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA EP: 3.Strategies for Managing Treatment-Naïve CLL with High-Risk Features EP: 4.Impact of Off-Target AEs and Treatment Resistance on Evolving 1L ...
Dr. Cortes on the Future of Ponatinib in CML Treatment Dr. Sweet on Key Findings From the OPTIC Trial With Ponatinib in CML Dr. Sweet on the Awareness and Mitigation of AEs Associated With Ponatinib in CML Dr. Hobbs on Choosing Optimal Second-Line Treatment Option for TKI-Resistant C...
Treatment options for chronic myeloid leukemia INTRODUCTION: The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for chronic myeloid leukemia (CML). However, there are many topic... MF Tanaka,H Kantarjian,J Cortes,... - 《Expert Opinion on Pharmacotherapy》 被引量: 60发...
Treatment options for leukemia and lymphoma Cancer research has shown that each person’s response to cancer treatment is unique. No two treatment plans are exactly the same. That’s why we work closely with you to create a personalized treatment plan unique to you. Depending on what type of...
BACKGROUND: The treatment options for bcr-abl positive chronic myelogenous leukemia (CML) include chemotherapy, immune therapy, allogeneic stem cell transplantation, and molecular therapy. The tyrosine kinase inhibitor imatinib was approved for the treatment of CML in 2002. Data from clinical trials all...